Kura Oncology Total Debt vs. Book Value Per Share
| KURA Stock | USD 9.98 0.35 3.63% |
For Kura Oncology profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Kura Oncology to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Kura Oncology utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Kura Oncology's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Kura Oncology over time as well as its relative position and ranking within its peers.
Kura |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kura Oncology. If investors know Kura will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kura Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.35) | Return On Assets (0.29) | Return On Equity (0.46) |
The market value of Kura Oncology is measured differently than its book value, which is the value of Kura that is recorded on the company's balance sheet. Investors also form their own opinion of Kura Oncology's value that differs from its market value or its book value, called intrinsic value, which is Kura Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kura Oncology's market value can be influenced by many factors that don't directly affect Kura Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kura Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Kura Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kura Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Kura Oncology Book Value Per Share vs. Total Debt Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Kura Oncology's current stock value. Our valuation model uses many indicators to compare Kura Oncology value to that of its competitors to determine the firm's financial worth. Kura Oncology is rated below average in total debt category among its peers. It is rated below average in book value per share category among its peers . The ratio of Total Debt to Book Value Per Share for Kura Oncology is about 3,155,384 . At present, Kura Oncology's Book Value Per Share is projected to increase based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Kura Oncology's earnings, one of the primary drivers of an investment's value.Kura Total Debt vs. Competition
Kura Oncology is rated below average in total debt category among its peers. Total debt of Health Care industry is now estimated at about 1.09 Billion. Kura Oncology claims roughly 17.2 Million in total debt contributing just under 2% to equities under Health Care industry.
Kura Book Value Per Share vs. Total Debt
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Kura Oncology |
| = | 17.2 M |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
Kura Oncology |
| = | 5.45 X |
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
Kura Book Value Per Share Comparison
Kura Oncology is currently under evaluation in book value per share category among its peers.
Kura Oncology Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Kura Oncology, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Kura Oncology will eventually generate negative long term returns. The profitability progress is the general direction of Kura Oncology's change in net profit over the period of time. It can combine multiple indicators of Kura Oncology, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -1.3 M | -1.3 M | |
| Operating Income | -165.8 M | -157.5 M | |
| Income Before Tax | -152.6 M | -145 M | |
| Net Loss | -152.6 M | -145 M | |
| Total Other Income Expense Net | 13.2 M | 13.8 M | |
| Net Loss | -143 M | -135.8 M | |
| Net Loss | -122.3 M | -116.1 M | |
| Income Tax Expense | 206.1 K | 216.4 K | |
| Interest Income | 12.6 M | 13.3 M | |
| Non Operating Income Net Other | 4.9 M | 2.8 M | |
| Net Interest Income | 11.2 M | 11.8 M | |
| Change To Netincome | 30.3 M | 31.9 M | |
| Net Loss | (2.08) | (2.19) | |
| Income Quality | 0.82 | 0.63 | |
| Net Income Per E B T | 0.90 | 0.80 |
Kura Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Kura Oncology. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Kura Oncology position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Kura Oncology's important profitability drivers and their relationship over time.
Use Kura Oncology in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Kura Oncology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Kura Oncology will appreciate offsetting losses from the drop in the long position's value.Kura Oncology Pair Trading
Kura Oncology Pair Trading Analysis
The ability to find closely correlated positions to Kura Oncology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Kura Oncology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Kura Oncology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Kura Oncology to buy it.
The correlation of Kura Oncology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Kura Oncology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Kura Oncology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Kura Oncology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Kura Oncology position
In addition to having Kura Oncology in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Aggressive Funds Thematic Idea Now
Aggressive Funds
Funds or Etfs that attempt to achieve high capital gains by investing in companies with high growth potential and above average risk. The Aggressive Funds theme has 43 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Aggressive Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Correlation Analysis. For information on how to trade Kura Stock refer to our How to Trade Kura Stock guide.You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
To fully project Kura Oncology's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Kura Oncology at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Kura Oncology's income statement, its balance sheet, and the statement of cash flows.